To enhance the efficacy of DNA malaria vaccines, we evaluated the effect on protection of immunizing with various combinations of DNA, recombinant vaccinia virus, and a synthetic peptide.
After inoculation by mosquitoes, Plasmodium spp. sporozoites rapidly enter hepatocytes, where they develop to mature liver stage parasites during Ϸ2 days for the rodent parasite, Plasmodium yoelii (Py), and 5.5 days for the human pathogen, Plasmodium falciparum. This stage of the life cycle does not cause disease and is the only stage during which parasites reside in cells that consistently express major histocompatibility complex molecules.
One approach to malaria vaccine development is to induce protective CD8ϩ T cell responses to infected hepatocytes (1) . This effort is in large part based on work in rodents that demonstrate that protective immunity induced by immunizing with irradiated sporozoites (2) (3) (4) or with DNA plasmids encoding Py proteins expressed in infected hepatocytes is eliminated by in vivo depletion of CD8ϩ T cells (5, 6) .
The Py circumsporozoite protein (PyCSP) is present within Py-infected hepatocytes. In BALB͞c mice immunized with PyCSP DNA vaccines, protection has varied from 22% to 75% (5, 6, 7) and is always dependent on CD8ϩ T cells. Protective immunity can be increased, and genetic restriction of the response to each individual protein can be circumvented by immunizing with mixtures of plasmids encoding liver stage proteins (6) . Based on our work in mice, we have recently initiated a Phase I clinical trial of a P. falciparum CSP DNA vaccine designed to induce protective CD8ϩ T cells (8) .
To improve the protection afforded by the PyCSP DNA vaccine, we assessed sequential immunization with DNA, recombinant vaccinia, and synthetic peptide PyCSP vaccines. These experiments indicated that priming with PyCSP DNA and boosting with recombinant vaccinia expressing PyCSP were associated with greater immunogenicity and protective immunity than priming and boosting with PyCSP DNA alone.
MATERIALS AND METHODS
Mice. BALB͞cByJ female mice (6-8 wk old) purchased from The Jackson Laboratory were used in all experiments.
Parasites. P. yoelii (17XNL) clone 1.1 parasites were used. Sporozoites for challenges were obtained by hand dissection of infected mosquito glands in M199 medium containing 5% normal mouse serum.
Plasmid Constructions. Two PyCSP DNA vaccines were used in this study. The plasmid designated 1012͞tissue plasminogen activator protein leader peptide sequence (TPA)-PyCSP contained the DNA sequence encoding the full-length PyCSP, which included the native leader peptide sequence, fused in-frame with the leader peptide sequence from human tissue plasminogen activator protein. The 1012-PyCSP plasmid encoded no additional in-frame residues. The PyCSP encoding sequence was amplified by PCR from the plasmid nkCMVintPyCSP.1 (5). The resultant product was Pfu polymerase treated (Stratagene) and was gel-purified and ligated with the EcoRV-digested plasmid nkCMVintPolyLi. From this plasmid, the PyCSP encoding sequence was recovered on a SalI͞XbaI fragment that was ligated with SalI͞XbaI-digested VR1012 (9), which created the plasmid designated 1012-PyCSP. From the nkCMVintPolyLi͞PyCSP plasmid, the PyCSP encoding sequence was recovered on a BamHI fragment and then was ligated with BamHI-digested pCMVintBL plasmid (10) , which placed the coding sequence in-frame with the TPA. From this plasmid, the TPA-PyCSP encoding sequence was recovered on a SalI͞BglII fragment that was ligated with SalI͞BglII-digested VR1012, creating the plasmid designated 1012͞TPA-PyCSP. The ability of these plasmids to express PyCSP was confirmed in vitro by using an anti-PyCSP mAb (11) and transiently transfected UM449 human melanoma cells (12) . All DNA for injection was purified as described (8) by using cesium chloride-ethidium bromide density gradient centrifugation. DNA was solubilized in United States Pharmacopia saline for injection at Ϸ5.0 mg͞ml and was stored at Ϫ20°C.
Recombinant Vaccinia Expressing PyCSP. The P. yoelii 17X NL CSP gene (nucleotides 1-1757) (13) was cloned into the multiple cloning site COPAK H6 donor plasmid. The expression plasmid pMK4 was used in vivo to generate a recombinant virus (vP 1258) by using a New York Vaccinia (NYVAC) rescuing virus (14) . The COPAK donor plasmid contains multiple cloning sites, with the gene of interest being placed under the control of an early-late H6 promoter (15) . The plasmid also carries the K1L ORF flanked on either side with ORFs of the A24R and A27L (16) . The foreign gene and the K1L gene are inserted into the ATI site of the NYVAC genome between the A24R and A27L ORFs. NYVAC virus differs from NYVAC(K1L) virus only by the absence of the K1L insertion. A control virus called vP993, containing a K1L insert but no foreign gene, was used as a control.
Immunizations with DNA Vaccines. Mice were injected i.m. in the tibialis anterior muscle with PyCSP DNA. Negative control mice were injected with 1012͞TPA DNA lacking the PyCSP gene. A 0.3-ml insulin syringe with a 29 1 ⁄2G inch needle was used for all injections, and each single dose consisted of 100 g that was delivered in a total volume of 100 l and split between both legs. Either 9 wk (in Experiment 1) or 6 wk (in Experiment 2) after the first immunization, some groups of mice were boosted with the same dose of the PyCSP DNA (D-D) whereas some received either 10 Immunizations Using PyCSP Peptide. Mice were injected s.c. with 16 g of PyCSP peptide, MAP4(280-99)p2p30 consisting of four branches of SYVPSAEQILEFVKQISSQL and p2p30 (tetanus toxin), and a glycine-lysine core (17) mixed with Lipofectin (Life Technologies, Gaithersburg, MD) at 15 l per dose. Groups were boosted 9 wk later with the same dose of the peptide (P-P), PyCSP DNA (P-D), or recombinant vaccinia virus (P-V).
Antibody Response
Indirect f luorescent antibody test. The indirect fluorescent antibody test was used to detect anti-P. yoelii sporozoite antibodies in sera of immunized mice as described (18) . In brief, diluted sera were reacted on air-dried sporozoites, and antibodies were detected by using fluorescein isothiocyanatelabeled rabbit anti-mouse Ig.
T Cell Assays
Cytotoxic T lymphocyte (CTL) Assays.
51
Chromium release assays using bulk cultures were performed on individual mice as described (5) . In brief, spleen cells (5 ϫ cells (American Type Culture Collection) labeled with 0.1 mCi of 51Cr (Dupont͞NEN) and pulsed with the PyCSP (280-288) peptide at 0.025 M were used as target cells. Varying ratios of effector cells were added to 5,000 target cells in a 96-well U-bottom plate, standard chromium release methods were followed, and the percentage of specific lysis was calculated. The results are expressed as mean net percentage of specific lysis. The net percentage of specific lysis was calculated by subtracting the percentage of specific lysis of unpulsed target cells from the percentage of specific lysis of target cells pulsed with the experimental peptide PyCSP (280-288). The mean net percentage of specific lysis was the average of net percentages of specific lysis at each effector-to-target ratio of cells from the two mice studied per group.
ELIspot Assay for the Detection of Interferon (IFN)-␥-Producing Spleen Cells. By using methods described by Miyahira et al. (19) , spleen cells from mice at 14 days after the second immunization were used. This was at the time when the others were being challenged. In Experiment 1, spleen cells from two individual mice were assayed, and in Experiment 2, pooled spleen cells from two mice were used. The number of H-2K d -restricted CTL epitope-specific IFN-␥ -producing cells was determined in freshly isolated, unstimulated spleen cells 24-28 hr after being incubated with P815 cells (express Class I but not Class II major histocompatibility complex molecules) pulsed with 1 M of the H-2K d -restricted PyCSP (280-288) peptide.
Ninety-six-well nitrocellulose plates (Millipore) were coated with 75 l of PBS containing 1 g͞ml of purified rat antimouse IFN-␥ antibody (PharMingen). After overnight incubation at room temperature, the wells were washed repeatedly with culture medium and were incubated for 1 hr with 100 l of culture medium containing 10% fetal calf serum. 100 l of varying concentrations of effector cells together with 100 l of 2.5 ϫ 10 5 cells͞ml irradiated P815 cells were placed in the antibody-coated wells. The starting concentration for the freshly isolated unstimulated effector cells was 30 ϫ 10 6 ͞ml, and doubling dilutions were assayed. One set of effector cells was cocultured with irradiated P815 cells that had been pulse-labeled with 1 M PyCSP(280-288) peptide. The other set of cells was cocultured with irradiated P815 cells without peptide.
After incubation at 37°C and 5% CO 2 for 24-28 hr, plates were washed extensively with PBS containing 0.05% Tween 20 (PBS͞ T). Wells then were incubated with 100 l of a solution of 1 g͞ml biotinylated anti-mouse IFN-␥ mAb (PharMingen) in PBS͞T. After overnight incubation at 4°C, wells were washed with PBS͞T and 100 l of peroxidase-labeled streptavidin (Kirkegaard and Perry, Gaithersburg, MD) at a dilution of 1͞1000 in PBS͞T, was added to each well. After 1 hr incubation at room temperature, wells were washed extensively with PBS͞T and twice with PBS. Spots were developed per instructions with the DAB Reagent set (Kirkegaard and Perry Laboratories). After 10-15 min, numbers of spots were determined by using a stereomicroscope. Spots corresponding to IFN-␥-producing cells in wells containing the different spleen cell dilutions were counted. Results were expressed as the number of IFN-␥-spot forming cells (SFCs) per 10 6 spleen cells.
Protection Against Challenge. Two wk after the second immunization, mice were challenged by i.v. inoculation in the tail vein of 50 viable P. yoelii sporozoites. Mice were considered protected if malaria blood films taken from day 5 until day 14 after challenge were negative by microscopy.
Statistical Analysis. The degree of protection afforded by the different immunization regimens was evaluated by using the Table 1 ). Mice that received two doses of 1012͞TPA-PyCSP DNA (D-D) had the next highest level of protection (7 of 16, 44%) ( Table 1) . Only these two groups had statistically significant protection on day 14 as compared with the pooled controls (P Ͻ 0.0001, D-V; P ϭ 0.0006, D-D). All groups except the D-D group had significantly fewer protected mice than did the group primed with PyCSP DNA and boosted with NYVAC(K1L)-PyCSP (D-V) ( Table 1 , P Ͻ 0.02, 2 ) and groups D-P, V-D, V-P, P-P, and P-D had significantly less protection (P Ͻ 0.05, 2 ) than did the D-D group. However, some of the mice in three other groups did not develop parasitemia (Table 1 ). There was also a statistically significant delay in onset of parasitemia in four other groups: D-P, V-V, P-D, and P-V (P Ͻ 0.0001, 2 . Based on a 24-hr cycle in erythrocytes and a 10-fold increase in parasitemia each cycle (average of 15 nuclei per each mature erythrocytic stage parasite), a one-day delay in onset of parasitemia would represent a 90% reduction in parasite burden. This indicates that, in mice with a delay in onset of parasitemia, vaccine-induced immune responses had a significant effect on parasite development in the liver. All of the three groups primed with DNA, 2͞3 of the groups primed with PyCSP CTL MAP, and only 1͞3 of the groups primed with NYVAC(K1L)-PyCSP had statistically significant protection or delay in the onset of parasitemia as compared with controls (Table 1) .
RESULTS AND DISCUSSION
Antibody Responses. We assessed antibodies to native protein on sporozoites by indirect fluorescent antibody test in sera taken before sporozoite challenge in half of the mice in each group (Fig.  1) . Mice in the D-V group, the group with the highest level of protection, had significantly higher antibody titers than did all other groups (Mann-Whitney U test, P ϭ 0.0008). However, pre-challenge antibody levels in individual mice did not predict protection; three of the six mice with the highest levels of antibodies were not protected (Fig. 1) . The D-D group, the only other group with significant protection, had antibody levels similar to mice in the V-D and V-V groups, groups without significant protection. Furthermore, in the D-D group, three of seven mice with the highest levels of antibodies were not protected. These data are consistent with our previous data and that of others (refs. 5 and 6; L. F. Scheller & S.L.H., unpublished material), which indicate that antibodies to sporozoites do not play a significant role in the protective immunity induced by the PyDNA vaccines, the Py irradiated sporozoite vaccine (2), the PyCSP CTL MAP or PyCSP recombinant vaccinia vaccines, or the Plasmodium berghei CSP recombinant vaccinia vaccines (20) . The fact that the group with the highest level of protection (D-V) had the highest level of antibodies suggests that the antibody responses in this group may have been associated with other immune responses responsible for protection.
Cytotoxic T Cell Responses. After a single injection in the two mice tested per group, both mice immunized with 1012͞TPA-PyCSP had higher levels of CTL activity against the 9-aa, H-2K drestricted CTL epitope on the PyCSP than did mice immunized with the two other vaccines, and the mean net percentage of specific lysis of the two mice immunized with PyCSP DNA was the highest (Fig. 2A ). Mice immunized with NYVAC(K1L)-PyCSP had the next highest level, and mice immunized with the PyCSP CTL MAP had the lowest level of cytolytic activity.
After two doses, the best responses were seen in the two D-V mice, the group best protected. Even at the lowest effector-totarget cell ratio (E͞T) of 20:1, both mice in the D-V group had greater net percentages of specific lysis (63% and 60%) than all mice in all the other groups at any E͞T ratio with the exception of one mouse at an E͞T ratio of 60:1 (62%) in the V-D group and one mouse at an E͞T ratio of 40:1 in the D-D group. The mean net percentage of specific lysis of the two D-V mice was higher than the mean net percentage of specific lysis of mice in all other groups (P ϭ 0.013, Mann-Whitney U test) (Fig. 2B) . Similar to the antibody data, mice from groups without significant protection had CTL activity comparable to mice in the D-D group that did have significant protection. These results must be interpreted (6) . One interpretation of these data is that the protection is not dependent on cytolytic CD8ϩ T cells but rather on CD8ϩ T cells that secrete IFN-␥, and that INF-␥ induces the infected hepatocyte to produce nitric oxide, which kills the parasite (2, 6). We therefore assessed IFN-␥ secretion by ELIspot in spleen cells taken 2 wk after the second immunization. Major histocompatibility complex-matched P815 cells (expressing Class I but not Class II molecules) pulsed with the 9-aa, H-2K (Fig. 3A) . As with the antibody and CTL data, the only other group with significant protection, the D-D group, did not have higher numbers of IFN-␥ SFCs than did mice from several other groups with no significant protection. Furthermore, one of the mice primed with peptide and boosted with NYVAC(K1L)-PyCSP had an excellent response. This group had only modest protection (3 of 16 mice completely protected during 14 days of follow-up). We cannot test cells from spleens from challenged mice at the time of challenge and therefore cannot determine whether a mouse with high activity actually would be protected. . In all comparisons, the group primed with PyCSP DNA and boosted with NYVAC(K1L)-PyCSP had a higher level of protection. The probability of this happening at random is 0.063. However, groups were small, and in only one of these comparisons were the differences statistically significant; D2-V vs. D2-D2 (P ϭ 0.02, 2 ). In the two experiments (Tables 1 and 2 ), 40 mice were ). We are unaware of any studies in which antibodies, Class I-restricted CTL and INF-␥ production, and protection against challenge with an infectious agent in animals primed with DNA and boosted with recombinant virus were shown to be higher than in animals primed and boosted with DNA. Primary immunization with a DNA vaccine and boosting with a recombinant fowl pox virus encoding the hemagglutinin antigen of influenza virus induced antibody levels in mice 30-to 120-fold higher than did either DNA or recombinant virus alone and induced protection against death in mice challenged with live influenza virus equivalent to that achieved with immunization with live virus alone or DNA alone (21) . Immunization of sheep with DNA followed by recombinant adenovirus expressing Taenia ovis produced higher levels of antibody than did immunizing with protein͞virus regimens and also produced high levels of protection (22) . However, DNA͞recombinant virus immunization was not compared with a DNA͞DNA regimen. In another study, antibody titers induced in rabbits with 4-6 doses of DNA were increased by boosting with recombinant virus (23) . In a mouse tumor model, immunization with a DNA vaccine and boosting with either a recombinant vaccinia or fowl pox induced antigen-specific CTL. Order of the immunization was also important; if the virus was given first and boosted with DNA, no lytic activity was noted. Boosting with an immunogen different from the one used for immunization (i.e., heterologous boosting) also produced increases in survival compared with animals receiving homologous boosts (24) .
The immunogenicity of the D-V approach was greater than that of all other approaches we studied and, when coupled with the higher protection in these mice, suggested that these antibody and T cell assays predicted protection. However, the D-D group also was protected significantly in Experiment 1, but immune responses in these D-D mice were not significantly higher than in mice without significant protection. One explanation for this discrepancy is that we did not measure the appropriate immune responses or that our assays need refinement. The results in the D-V mice (the best immune responses and the best protection) could be a reflection of the global immune responses being greatest in these mice rather than any of the measured immune responses being critical for protection. The results also could have been influenced by the fact that we did not assay T cells from individual mice that then were challenged but rather took cells from spleens of mice that were not challenged. In these experiments, Յ69% of mice within a group were protected, and this variability in protection could explain why the results of testing cells from nonchallenged mice was not accurate in predicting protection.
These data demonstrate that priming with PyCSP DNA and boosting with recombinant vaccinia expressing PyCSP is more immunogenic and protective than is priming and boosting with PyCSP DNA or with vaccinia-PyCSP or priming with vacciniaPyCSP and boosting with PyCSP DNA. Li and colleagues (24) reported that priming with recombinant influenza expressing the PyCSP H-2K d -restricted CTL epitope and boosting with vacciniaPyCSP was more protective than immunizing with either alone or with vaccinia-PyCSP first and the recombinant influenza second. We expected, therefore, to achieve good protection by priming with the PyCSP CTL MAP, which included the same epitope as the recombinant influenza. Priming with the CTL MAP and boosting with vaccinia PyCSP was associated with good CTL activity and IFN-␥ production and a significant delay in onset of parasitemia but 19% complete protection (not significant).
Our results are consistent with those of Li (25) in regard to the need for delivering the recombinant vaccinia as the boosting rather than the priming dose. We do not have an explanation for either this requirement or the enhanced immunogenicity of the D-V approach as compared with the D-D approach. When using recombinant influenza or other viruses, it is always possible that the host develops immunity to the virus portion of the immunogen, thereby limiting the response to a booster dose. However, we have no evidence that this occurs with DNA and usually have seen good boosting with second and third doses of DNA (5, 26) . It may be that the critical event in priming depends on the quality of the immunogen (DNA better than vaccinia) and that boosting is more dependent on the quantity of immunogen expressed (vaccinia better than DNA). Work is in progress to more clearly characterize how sequential immunization with PyCSP DNA and vaccinia-PyCSP improves the response to vaccination. Nonetheless, we think that these findings support assessing sequential immunization with plasmid DNA and recombinant vaccinia in humans.
